Show Search Form

Search Results

registered interest	true false
date	exactly: or between: and
answering body
answering dept id
answering dept short name
answering dept sort name
hansard heading
house id
legislature	pref label
question text
tabling member printed
uin
answer	is ministerial correction true false date of answer exactly: or between: and answer text answering member printed grouped question UIN question first answered answering member label attachment file name title
tabling member	label

Search

1718117

	registered interest
	date	14/05/2024
	answering body	Department of Health and Social Care
	answering dept id	17
	answering dept short name	Health and Social Care
	answering dept sort name	Health and Social Care
	hansard heading	Breast Cancer: Ethnic Groups
	house id	2
	legislature	25277 pref label House of Lords
	question text	To ask His Majesty's Government what progress they have made in reducing inequalities in outcomes for breast cancer patients from black and minority ethnic backgrounds over the past (1) 10 years, (2) five years, and (3) two years.
	tabling member printed	Baroness Merron
	uin	HL4629
	answer	answer is ministerial correction date of answer 21/05/2024 answer text <p>Reducing inequalities and improving breast cancer outcomes for ethnic minority women is a priority for the Government. To support this work, NHS England has commissioned six new cancer clinical audits, which will provide timely evidence for cancer service providers of where patterns of care in England may vary, increase the consistency of access to treatments, and help stimulate improvements in cancer treatments and outcomes for patients, including for breast cancer. The Royal College of Surgeons began work on this audit in October 2022, and the first outcomes are expected in September 2024.</p><p>NHS England is also leading a programme of work to tackle healthcare inequalities centred around five clear priorities, which are set out in the operational planning guidance for the health system. The Core20PLUS5 approach proactively targets groups that are less likely to engage with services in the most deprived quintile of the population, along with ethnic minority communities and inclusion health groups, across five clinical areas which includes early cancer diagnosis, specifically screening and early referral.</p><p>The issue of improving equality monitoring, by reference to ethnicity and the other eight protected characteristics, is being considered at a national level under the programme called the Unified Information Standard for Protected Characteristics (UISPC). Evaluating the use of the 2021 ethnicity census categories is part of this programme. The UISPC Publication Steering Group is reporting to NHS England and the Department this year, which will inform a view on the next steps, including any plans for publication and consultation, and an implementation timetable. Preparatory work has been undertaken by NHS England that would facilitate the introduction of the 2021 ethnicity codes, should a decision be made to adopt the 2021 ethnicity census codes, or to implement an alternative approach to ethnicity, if recommended.</p><p>NHS England’s operational planning guidance recognises the importance of improving the quality of data for patient characteristics. This is one of the five strategic priorities in their drive to reduce healthcare inequalities, as improved data quality will help to reveal health inequalities and inform action to address them. NHS England has therefore asked systems to continue to improve the collection and recording of ethnicity data across primary care, outpatients, accident and emergency, mental health, community services, and specialised commissioning.</p><p>NHS England’s National Disease Registration Service (NDRS) collects ethnicity data for all cancer patients through a variety of routine, national data feeds, including the Cancer Outcomes and Services Dataset, Hospital Episode Statistics data, and Patient Administration System data. The NDRS publishes key performance indicator data on the national registration statistics for England. The latest published indicator data, for invasive cancer cases excluding non-melanoma skin cancers, diagnosed in 2020, shows that ethnicity data is complete for 94.9% of cases.</p> answering member printed Lord Markham grouped question UIN HL4631 question first answered 21/05/2024 11:11:25 answering member 4948 label Biography information for Lord Markham
	tabling member	347 label Biography information for Baroness Merron

1718119

	registered interest
	date	14/05/2024
	answering body	Department of Health and Social Care
	answering dept id	17
	answering dept short name	Health and Social Care
	answering dept sort name	Health and Social Care
	hansard heading	Breast Cancer: Health Services
	house id	2
	legislature	25277 pref label House of Lords
	question text	To ask His Majesty's Government what steps they are taking to improve the collection and reporting of ethnicity data for breast cancer patients to support understanding of variations in outcomes and patient experience of NHS care.
	tabling member printed	Baroness Merron
	uin	HL4631
	answer	answer is ministerial correction date of answer 21/05/2024 answer text <p>Reducing inequalities and improving breast cancer outcomes for ethnic minority women is a priority for the Government. To support this work, NHS England has commissioned six new cancer clinical audits, which will provide timely evidence for cancer service providers of where patterns of care in England may vary, increase the consistency of access to treatments, and help stimulate improvements in cancer treatments and outcomes for patients, including for breast cancer. The Royal College of Surgeons began work on this audit in October 2022, and the first outcomes are expected in September 2024.</p><p>NHS England is also leading a programme of work to tackle healthcare inequalities centred around five clear priorities, which are set out in the operational planning guidance for the health system. The Core20PLUS5 approach proactively targets groups that are less likely to engage with services in the most deprived quintile of the population, along with ethnic minority communities and inclusion health groups, across five clinical areas which includes early cancer diagnosis, specifically screening and early referral.</p><p>The issue of improving equality monitoring, by reference to ethnicity and the other eight protected characteristics, is being considered at a national level under the programme called the Unified Information Standard for Protected Characteristics (UISPC). Evaluating the use of the 2021 ethnicity census categories is part of this programme. The UISPC Publication Steering Group is reporting to NHS England and the Department this year, which will inform a view on the next steps, including any plans for publication and consultation, and an implementation timetable. Preparatory work has been undertaken by NHS England that would facilitate the introduction of the 2021 ethnicity codes, should a decision be made to adopt the 2021 ethnicity census codes, or to implement an alternative approach to ethnicity, if recommended.</p><p>NHS England’s operational planning guidance recognises the importance of improving the quality of data for patient characteristics. This is one of the five strategic priorities in their drive to reduce healthcare inequalities, as improved data quality will help to reveal health inequalities and inform action to address them. NHS England has therefore asked systems to continue to improve the collection and recording of ethnicity data across primary care, outpatients, accident and emergency, mental health, community services, and specialised commissioning.</p><p>NHS England’s National Disease Registration Service (NDRS) collects ethnicity data for all cancer patients through a variety of routine, national data feeds, including the Cancer Outcomes and Services Dataset, Hospital Episode Statistics data, and Patient Administration System data. The NDRS publishes key performance indicator data on the national registration statistics for England. The latest published indicator data, for invasive cancer cases excluding non-melanoma skin cancers, diagnosed in 2020, shows that ethnicity data is complete for 94.9% of cases.</p> answering member printed Lord Markham grouped question UIN HL4629 question first answered 21/05/2024 11:11:25 answering member 4948 label Biography information for Lord Markham
	tabling member	347 label Biography information for Baroness Merron

1718156

	registered interest
	date	14/05/2024
	answering body	Department of Health and Social Care
	answering dept id	17
	answering dept short name	Health and Social Care
	answering dept sort name	Health and Social Care
	hansard heading	Drugs: Prices
	house id	2
	legislature	25277 pref label House of Lords
	question text	To ask His Majesty's Government what assessment they have made of the impact of the NHS England uniform pricing policy on patients' access to innovative medicines.
	tabling member printed	Lord Warner
	uin	HL4654
	answer	answer is ministerial correction date of answer 21/05/2024 answer text <p>NHS England has successfully secured patient access to a number of innovative medicines under its policy of uniform pricing. European industry data from April 2023 showed that for every four treatments available in Europe, there is an additional medicine available in England, and a quarter more cancer drugs available in England compared to the European average.</p> answering member printed Lord Markham question first answered 21/05/2024 12:26:39 answering member 4948 label Biography information for Lord Markham
	tabling member	1732 label Biography information for Lord Warner

1718157

	registered interest
	date	14/05/2024
	answering body	Department of Health and Social Care
	answering dept id	17
	answering dept short name	Health and Social Care
	answering dept sort name	Health and Social Care
	hansard heading	Drugs: Prices
	house id	2
	legislature	25277 pref label House of Lords
	question text	To ask His Majesty's Government how many commercial agreements NHS England has made with manufacturers of medicines which allow, support or result in non-uniform pricing by individual medicine.
	tabling member printed	Lord Warner
	uin	HL4655
	answer	answer is ministerial correction date of answer 21/05/2024 answer text <p>Since April 2020, NHS England has agreed to 37 commercial agreements that have resulted in non-uniform pricing by medicine, via either the Cancer Drugs Fund, or through bespoke commercial deals to support routine commissioning.</p> answering member printed Lord Markham question first answered 21/05/2024 12:26:52 answering member 4948 label Biography information for Lord Markham
	tabling member	1732 label Biography information for Lord Warner

1717435

	registered interest
	date	13/05/2024
	answering body	Department of Health and Social Care
	answering dept id	17
	answering dept short name	Health and Social Care
	answering dept sort name	Health and Social Care
	hansard heading	Health: Productivity
	house id	2
	legislature	25277 pref label House of Lords
	question text	To ask His Majesty's Government what plans they have to enable evaluation of health programmes and investments to account for productivity benefits, in line with guidance issued in the Green Book.
	tabling member printed	Baroness Ritchie of Downpatrick
	uin	HL4600
	answer	answer is ministerial correction date of answer 20/05/2024 answer text <p>The Department has well-established policies and mechanisms in place to ensure health programmes and investments are subject to systematic evaluation at key stages in their lifecycle, in accordance with HM Treasury’s business case guidance. This includes reviewing quantitative and qualitative evidence on whether approved health projects achieve their objectives and deliver the promised benefits within the agreed budget, timescale, and scope. Lessons from post-project evaluation are widely disseminated, to support better investment decisions in future, and more robustly developed business cases.</p> answering member printed Lord Markham question first answered 20/05/2024 10:34:42 answering member 4948 label Biography information for Lord Markham
	tabling member	4130 label Biography information for Baroness Ritchie of Downpatrick

1717405

	registered interest
	date	13/05/2024
	answering body	Department of Health and Social Care
	answering dept id	17
	answering dept short name	Health and Social Care
	answering dept sort name	Health and Social Care
	hansard heading	Tobacco and Vapes Bill
	house id	2
	legislature	25277 pref label House of Lords
	question text	To ask His Majesty's Government what data they collected on other countries that have restricted smoking when drafting the Tobacco and Vapes Bill.
	tabling member printed	Lord Bourne of Aberystwyth
	uin	HL4570
	answer	answer is ministerial correction date of answer 20/05/2024 answer text <p>Smoking is responsible for approximately 80,000 deaths a year in the United Kingdom and causes around one in four UK cancer deaths. It also costs society £21.8 billion a year and puts a huge burden on the National Health Service. The latest estimates from Action on Smoking and Health put the cost of smoking to the NHS and social care at £3 billion a year.</p><p>As part of our impact assessment, we reviewed evidence and data from a range of countries. This included modelling from New Zealand, Singapore, and the Solomon Islands on the estimated impact of a smokefree generation policy on smoking prevalence, smoking attributable mortality, and other health impacts. We also considered evidence and data from countries that have already implemented an increase in the age of sale for tobacco to a particular age. For example, we analysed data and evidence from the United States on the impact that raising the age of sale from 18 to 21 years old had on smoking prevalence.</p><p>This was in addition to considering evidence and data from the UK on the impact that previous increases in the age of sale for tobacco have had on smoking prevalence. A copy of our Tobacco and Vapes Bill - impact assessment is attached.</p> answering member printed Lord Markham question first answered 20/05/2024 15:06:35 answering member 4948 label Biography information for Lord Markham attachment 1 file name tobacco-vapes-bill-impact-assessment.pdf title tobacco-vapes-bill-impact-assessment
	tabling member	4282 label Biography information for Lord Bourne of Aberystwyth

1717421

	registered interest
	date	13/05/2024
	answering body	Department of Health and Social Care
	answering dept id	17
	answering dept short name	Health and Social Care
	answering dept sort name	Health and Social Care
	hansard heading	Cancer: Health Services
	house id	2
	legislature	25277 pref label House of Lords
	question text	To ask His Majesty's Government how many people diagnosed with cancer underwent a needs assessment and were given a personalised care and support plan in (1) 2021, (2) 2022, and (3) 2023.
	tabling member printed	Lord Kempsell
	uin	HL4586
	answer	answer is ministerial correction date of answer 21/05/2024 answer text <p>The information is not available, as the data is not collected in the format requested.</p> answering member printed Lord Markham grouped question UIN HL4587 question first answered 21/05/2024 11:09:03 answering member 4948 label Biography information for Lord Markham
	tabling member	4988 label Biography information for Lord Kempsell

1717422

	registered interest
	date	13/05/2024
	answering body	Department of Health and Social Care
	answering dept id	17
	answering dept short name	Health and Social Care
	answering dept sort name	Health and Social Care
	hansard heading	Cancer: Health Services
	house id	2
	legislature	25277 pref label House of Lords
	question text	To ask His Majesty's Government how many people who completed cancer treatment were offered an 'end of treatment summary' in (1) 2021, (2) 2022, and (3) 2023.
	tabling member printed	Lord Kempsell
	uin	HL4587
	answer	answer is ministerial correction date of answer 21/05/2024 answer text <p>The information is not available, as the data is not collected in the format requested.</p> answering member printed Lord Markham grouped question UIN HL4586 question first answered 21/05/2024 11:09:03 answering member 4948 label Biography information for Lord Markham
	tabling member	4988 label Biography information for Lord Kempsell

1717423

	registered interest
	date	13/05/2024
	answering body	Department of Health and Social Care
	answering dept id	17
	answering dept short name	Health and Social Care
	answering dept sort name	Health and Social Care
	hansard heading	Cancer: Health Services
	house id	2
	legislature	25277 pref label House of Lords
	question text	To ask His Majesty's Government what steps they will take to ensure equity and quality in care and support across the entire cancer pathway, including (1) fairness and equity in diagnostics, (2) on time treatment, and (3) patients being offered conversations about the additional care and support they may need.
	tabling member printed	Lord Kempsell
	uin	HL4588
	answer	answer is ministerial correction date of answer 20/05/2024 answer text <p>The Department is taking steps to ensure equity and quality in care and support for patients is available across the entire cancer pathway. Reducing inequalities and variation in cancer diagnosis and treatment are a priority for the Government, as is increasing early cancer diagnosis, as this is a key contributor to reducing cancer health inequalities. The Government is working jointly with NHS England on implementing the delivery plan for tackling the COVID-19 backlogs in elective care, and plans to spend more than £8 billion from 2022/23 to 2024/25 to help drive up and protect elective activity, including cancer diagnosis and treatment activity. As part of this, we are increasing diagnostic capacity by rolling out community diagnostic centres across England, with capacity prioritised for cancer checks. Additionally, and as outlined in the 2024/25 NHS England Planning Guidance, NHS England is providing over £266 million in cancer service development funding to Cancer Alliances, to support delivery of the operational priorities for cancer.</p><p>The Department's ministers and officials frequently meet with key stakeholders within the cancer community, including discussions on support for patients and their families. The National Health Service provides personalised cancer care and support plans, to support both patients and their families at all stages of their cancer journey. This is being delivered in line with the NHS Comprehensive Model for Personalised Care, empowering people to manage their care and the impact of their cancer, and maximise the potential of digital and community-based support.</p><p>General practice surgeries also conduct cancer care reviews at regular intervals after cancer diagnosis, to offer support with any needs patients may have. This includes providing access to other specialist-led services who work alongside patients’ medical teams, to support patients and their families, such as counsellors, rehabilitation specialists, or social prescribers, who can connect you to community groups or services for more support.</p><p>NHS England and the integrated care boards are responsible for commissioning and ensuring the healthcare needs of local communities in England are met, including for cancer patients. NHS England provides access to a personal health budget, which is an amount of NHS money that is allocated to support the health and wellbeing needs of a patient, if eligible.</p> answering member printed Lord Markham question first answered 20/05/2024 15:19:21 answering member 4948 label Biography information for Lord Markham
	tabling member	4988 label Biography information for Lord Kempsell

1717437

	registered interest
	date	13/05/2024
	answering body	Department of Health and Social Care
	answering dept id	17
	answering dept short name	Health and Social Care
	answering dept sort name	Health and Social Care
	hansard heading	Pharmacy: Drugs
	house id	2
	legislature	25277 pref label House of Lords
	question text	To ask His Majesty's Government what assessment they have made of the (1) level, and (2) geographical distribution, of drug shortages in pharmacies.
	tabling member printed	The Lord Bishop of St Albans
	uin	HL4602
	answer	answer is ministerial correction date of answer 20/05/2024 answer text <p>The Department monitors and manages medicine supply issues at a national level, so that stocks remain available to meet regional and local demand. We receive notifications of supply issues from United Kingdom medicine license holders. In 2022 and 2023, the number of notifications of supply issues remained broadly stable, at approximately 1,600 per year.</p> answering member printed Lord Markham question first answered 20/05/2024 15:11:51 answering member 4948 label Biography information for Lord Markham
	tabling member	4308 label Biography information for The Lord Bishop of St Albans